2019 Exhibitors

Booth 2: MIM Software Inc
MIM Software Inc. offers a powerful combination of tools available for:

  • Prostate LDR Brachytherapy TPS for all ultrasound manufacturers and direct connection with BK Ultrasound®.
  • Breast Microseed Treatment® software exclusively from Concure Oncology®.
  • MRI-guided fusion integrated with BK Ultrasound for those optimizing HDR implantation.
  • CT, US, and MRI fusion integration into treatment planning for enhanced planning accuracy, quality assurance, and timesavings.

The MIM Software advantage comprises a complete pathway solution for prostate cancer and breast cancer management. Please visit https://www.mimsoftware.com/ for prostate fusion and LDR products and http://www.breastmicroseed.com/ for Concure Oncology.

 

Booth 3: 3D Biopsy/Simulated Inanimate Models LLC
3DBiopsy, Inc. is developing a new system to diagnose cancer earlier and more accurately, using a low-cost set of new instruments to replace over 30-year-old technology. 3DBiopsy’s system consists of a patented biopsy actuator device, patented needle designs, new image-guided software and a new pathology specimen handling system. The Company’s system has the potential to replace inaccurate biopsy techniques of which there are over 20 million performed per year worldwide. The Company’s initial focus is on prostate cancer.

Simulated Inanimate Models LLC (SIM) manufactures synthetic, lifelike physical anatomical models to enable surgeons to train to competency with zero risk to the patient. The company is focused on shifting surgical training out of the operating room and into a simulated educational environment using a patent-pending system. SIM’s training models are able to replicate all steps of a complete operating room procedure, including pre-operative planning, pre- and intraoperative imaging (MRI, CT and ultrasound), and procedure-specific functionality. SIM is constantly working to develop technological and educational innovations that improve patient safety and broadly increase the quality of healthcare delivered.

 

Booth 5: Varian Medical Systems
Varian Medical Systems focuses energy on saving lives by equipping the world with advanced technology for fighting cancer. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. For more information, visit www.varian.com/brachytherapy.

 

Booth 6: Mobius
Mobius Imaging is the premier developer and supplier of best-in-class large bore diagnostic and intraoperative mobile CT imaging systems. Its Airo® 32 slice mobile, wide bore CT System provides intra-procedural diagnostic imaging supporting radiation therapy applications including brachytherapy.

 

Booth 7: Best Medical
Best Medical International now encompasses a family of trusted companies and organizations with a proven track record of innovation, quality and service in external beam radiation therapy, brachytherapy and vascular brachytherapy solutions. Our aim is to be the one partner that clinicians turn to for all their radiotherapy and oncology product and service requirements. TeamBest® can provide all your needs under one purchase order for external beam therapy and brachytherapy including:

 

Booth 8: Pyrexar Medical
Pyrexar Medical is the recognized global leader in thermal oncology medical devices. Our clinically proven systems provide targeted hyperthermia to solid tumors that increase the effectiveness of radiotherapy in the treatment of cancer. Hyperthermia provides increased blood flow and perfusion, shrinks tumor mass, inhibits DNA repair and can trigger and immune response. We offer systems that treat deep regionally, superficially and interstitially.

 

Booth 9: Boston Scientific-SpaceOAR
Augmenix was recently acquired by Boston Scientific. SpaceOAR™ hydrogel is now a member of the prostate health family of products within Boston Scientific. SpaceOAR hydrogel provides over 1 cm of space between the prostate and rectum to decrease rectal toxicity and minimize changes in quality of life (QOL) following prostate radiotherapy.

 

Booth 10 and 11: Qfix
Qfix is an innovative medical device company focused on discovering, developing and commercializing technology-driven solutions that are compatible in modalities ranging from linear accelerators, proton therapy, and imaging technologies. Qfix's primary focus is designing patient positioning and immobilization solutions that meet the unique physics of photon and proton beam transmission and allow for high precision treatment through reduced intra- and inter-fraction patient movement. We advance precise positioning solutions for cancer treatment by fostering a deep engagement with medical professionals. With the learning and relationships built from these deep ties, we are aggressively pursuing many cutting edge solutions, including Stereotactic Radiosurgery (SRS), Stereotactic Body Radiation Therapy (SBRT), Magnetic Resonance (MR) and Patient Transport. Log on to www.Qfix.com for more information.

 

Booth 12: IsoAid
As the manufacturer of Advantage™ I-125 and Pd-103 seeds for over 15 years, IsoAid specializes in providing brachytherapy seeds for the treatment of prostate, ocular and breast cancer, as well as for diagnostic localization purposes. We are a full-service company you can always rely on, making seeds at the activity you request, custom-loading and delivering them faster than anyone in the industry. Through our exclusive partnership with Eye Physics we give you access to cutting edge eye plaques and planning services, which deliver many clinical advantages to you and your patients. High-activity seeds are custom-loaded using COMS or Eye Physics plaques. Our innovate Secure Strand™, cuts down significantly on migration for prostate patients and is now being used for RSL with great success. Our team of experts is dedicated to helping with every aspect of your program and serves as a complete resource for you. IsoAid is invested in the future of Brachytherapy and we look forward to introducing you to some exciting new advances very soon.

 

Booth 13: Concure Oncology | Breast Microseed Inc.
Breast Microseed Treatment™ is a minimally invasive, post-lumpectomy outpatient radiation option for women with early-stage breast cancer, involving the permanent implantation of low-dose rate radiation sources (palladium seeds). The procedure is One Time, One Hour. With Breast Microseed Treatment, side effects are less severe, and because it is administered in a single, one-hour procedure, a quicker, simpler return to health and wellness becomes possible.

Breast Microseed Treatment's parent company, Concure Oncology®, specializes in early-stage breast cancer radiation treatment and related services. Concure Oncology provides the technology, protocol, education, equipment, and marketing support to major cancer centers offering Breast Microseed Treatment.

Concure Oncology/Breast Microseed, Inc is committed to easing the burden for women facing early-stage breast cancer by enhancing and simplifying radiation treatment so they can get back to living their lives.

Microseed

 

Booth 14: IsoRay
Isoray Medical passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Founded in 1998 to explore the medical use of Cesium 131 for the treatment of prostate cancer, Isoray's low dose rate (LDR) brachytherapy product was cleared by the FDA for treatment of various cancers. Since the first patient was treated with Isoray's Cesium product in October 2004, Isoray has provided products for over 10,000 patient treatments, including prostate cancer, brain, head & neck and gynecological tumors, and other isolated tumors and tumor beds.

Isoray has a dedicated team of employees who passionately work together to design, develop, produce and deliver products to address clinical needs and push the industry status quo with highly efficacious and patient-centric treatments.

IsoRay logo

 

Hitachi Booth 15: Hitachi Healthcare
Hitachi Healthcare's commitment to ultrasound in urology offers a wide range of consoles and specifically designed transducers to meet the needs of every doctor. Recognized for our superior image quality, system reliability and use of cutting edge technology, we remain the standard in the field of ultrasound.

 

Booths 16 & 17: Samsung Neurologica
NeuroLogica, a subsidiary of Samsung, brings the power of innovative imaging to your patients. With an expertise in CT design, NeuroLogica transforms fixed CT technologies into portable platforms used in many different clinical applications. The world's first portable, full body CT scanner, BodyTom is a self-shielded, multi-departmental imaging solution capable of transforming any room in the hospital into an advanced CT suite. The system features an 85cm gantry and a 6cm field of view, the largest field of view available in a portable CT scanner. BodyTom provides point-of-care imaging wherever high-quality CT images are needed, including the intensive care unit and radiation oncology suites. For more information, please visit www.NeuroLogica.com.

 

Booth 18: Theragenics
As an industry pioneer and leader, Theragenics has an unparalleled history of > 35 years in the manufacture and global supply of low-dose rate (LDR) brachytherapy seeds for the treatment of prostate cancer, lung cancer, intra-ocular malignancies, benign disease, and other solid tumors.  Theragenics continues to invest and develop innovative brachytherapy solutions, supported by the recent launch of Orion™, a novel, positive-signal MRI marker for HDR treatment planning. Please contact us to learn more about our industry benchmark recognized sources TheraSeed® Pd-103 & AgX100® I-125, and Orion MRI HDR Line Marker.

 

Booth 19: C4 Imaging LLC
C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate MRI guided procedures. LDR post-implant seed localization is achieved with the Sirius™ MRI Marker, along with a new MRI line marker for HDR planning. The company's core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that is encapsulated within a biocompatible shell.

 

Booth 21: CivaTech Oncology
CivaTech Oncology is dedicated to localized radiation, precision therapy without the beam. The implantable CivaSheet features a polymer encapsulated Pd-103 source, the only LDR brachytherapy device customizable to a specific patient and unidirectional to shield healthy tissue- the Gold side is Cold! CivaString is also a Pd-103 source with a unique linear radioactive distribution providing refinement on traditional prostate seeds- all polymer, no titanium, less needles, less swelling = less symptoms.

 

Booth 22: Orfit
Orfit brings high precision and comfort to the positioning and immobilization of cancer patients in Radiation Oncology. The Zephyr HDR system utilizes patented hover technology to allow patient transfer from procedure to imaging to treatment while maintaining patient positioning and minimizing the risk of needle/applicator displacement. Visit www.orfit.com for more information.

 

Booth 25: Elekta
Elekta pioneers significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, stateo-f-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.

Encompassing forty years innovation, Elekta's brachytherapy solutions are designed for precise, targeted treatment of various cancers such as prostate, breast, skin and surface, rectum and gynecological anatomy. The best-in-class clinical solutions include Flexitron® afterloading, Oncentra® Brachy treatment planning, Esteya® electronic brachytherapy, the broadest range of applicators in the industry and Real-time Prostate Solutions. To learn more, visit www.elekta.com/brachytherapy.

 

Tabletop Exhibitors

 

Tabletop A: AccuBoost
AccuBoost® is an innovative radiotherapy procedure: It uses real-time mammography image-guidance for targeting the radiation and a non-invasive HDR brachytherapy approach for delivering a conformal dose. Slight compression of the breast via a mammography platform allows the external tungsten applicators to be placed close to the tumor bed, minimizing exposure to healthy tissue for good cosmetic outcome.

 

Tabletop C: Siemens Medical Solutions USA, Inc.
At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare

Tabletop F: GT Medical Technologies
GT Medical Technologies is committed to improving the lives of patients with brain tumors. Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces and formed GT Medical Technologies to address this critical, unmet need. Extensive clinical expertise informed the design of GammaTile, which is a surgically targeted radiation therapy (STaRT) that provides immediate, dose-intense treatment at completion of brain tumor resection.

 

Tabletop G: CIVCO Medical Solutions
For over 30 years CIVCO Medical Solutions has been an industry leader in ultrasound, providing needle guidance solutions and infection control products across the spectrum of care. CIVCO offers a full range of steppers, stabilizers and accessories for transrectal and transperineal procedures.

 

Tabletop I: Myriad Medical LLC
Myriad Medical is a leading device company that develops treatment aids for radiation delivery. We develop simple solutions with the most clinically advanced technology to enhance the standard of care each patient deserves. For 8 years our prostate immobilization devices have been recognized for their non-invasive approach to reduce rectal toxicity. Myriad Medical's rectal balloon can reduce rectal dose and intra-fraction motion.

We understand the urgency for quality care when patients are diagnosed with cancer and the responsibility of medical professionals to provide the most advanced resources. Our devices are designed with cost effectiveness in mind, making our leading technology more accessible to healthcare providers nationwide.

 

Tabletop M: Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The recently introduced Sculptura™ robotic radiation oncology system provides targeted intraoperative triple-modulated radiotherapy (IORT) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently.

Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

 

 

Tabletop N: Xoft, a subsidiary of iCAD Inc.
The Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a radiation therapy solution FDA cleared for use anywhere in the body; including for the treatment of early stage breast cancer, gynecological cancers and skin cancer. Our proprietary, miniaturized x-ray source is isotope-free and operates at 50 kV to deliver high dose rate, low energy radiation.

Our transformative vision for the future of radiation therapy began with the breakthrough development of our miniaturized x-ray source – so small, it could fit on the tip of your finger. Today, this proprietary technology, combined with the comprehensive capabilities of the Xoft System, has powered the treatment of thousands of cancer patients worldwide. Every component of our advanced platform technology has been expertly engineered to improve quality of care, optimize operational workflow, and increase access to patient-centric, cutting-edge radiation therapy for patients and providers alike – all in one, innovative system. Our technology empowers physicians with full confidence to precisely and effectively treat cancer and enable their patients to live healthy, high-quality lives. Our commitment to this innovative technology is driven by the profound benefits it offers to physicians, facilities and patients on a global scale.

 

 

Tabletop O: Alpha TAU Medical Ltd.
Alpha Tau Medical is an Israeli biotech company focusing on R&D and commercialization of the first alpha-radiation-based brachytherapy, the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).

The treatment is delivered through intra-tumoral insertion of with Radium-224-impregnated seeds using ultra-minimally disposable applicators. The seeds release alpha-emitting atoms to a short distance of several millimeters around the seed, destroying the tumor while sparing healthy tissue.

Interim clinical results in patients with skin and oral cavity SCC and BCC showed high safety and efficacy, with negligibly low local toxicity, no negative systemic effects, 100% response and over 70% complete response. Further clinical collaborations with over 70 leading cancer centers worldwide have been initiated to investigate Alpha DaRT for various indications, including breast, pancreatic, prostate and lung cancer.

Initially developed at Tel Aviv University, Alpha DaRT was proven safe and effective for all solid tumors tested. These preclinical findings were published in 12 papers in peer-reviewed scientific journals.

For more information, visit: http://www.alphatau.com/.

 

Tabletop Q: Associates in Medical Physics (AMP)
Associates in Medical Physics (AMP) strives to provide the highest quality professional services to hospitals, clinics, and healthcare systems. Using medical and industrial radiation applications, we offer technical expertise for consultation, development, and management of applied radiation systems, including staffing and management solutions. AMP seeks out programs where we can augment and partner for great patient care.